Jensen Investment Management Inc. lessened its stake in Becton Dickinson and Co (NYSE:BDX) by 6.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,197,568 shares of the medical instruments supplier’s stock after selling 163,819 shares during the period. Becton Dickinson and accounts for approximately 6.0% of Jensen Investment Management Inc.’s investment portfolio, making the stock its largest holding. Jensen Investment Management Inc. owned about 0.82% of Becton Dickinson and worth $470,411,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of the business. Bollard Group LLC lifted its stake in shares of Becton Dickinson and by 1,910.3% in the 4th quarter. Bollard Group LLC now owns 7,438 shares of the medical instruments supplier’s stock valued at $1,592,000 after purchasing an additional 7,068 shares during the last quarter. Aull & Monroe Investment Management Corp lifted its stake in shares of Becton Dickinson and by 61.1% in the 4th quarter. Aull & Monroe Investment Management Corp now owns 2,577 shares of the medical instruments supplier’s stock valued at $552,000 after purchasing an additional 977 shares during the last quarter. Exane Derivatives lifted its stake in shares of Becton Dickinson and by 848.6% in the 4th quarter. Exane Derivatives now owns 702 shares of the medical instruments supplier’s stock valued at $150,000 after purchasing an additional 628 shares during the last quarter. IFM Investors Pty Ltd lifted its stake in shares of Becton Dickinson and by 16.2% in the 4th quarter. IFM Investors Pty Ltd now owns 7,376 shares of the medical instruments supplier’s stock valued at $1,579,000 after purchasing an additional 1,028 shares during the last quarter. Finally, BB&T Corp lifted its stake in Becton Dickinson and by 8.2% during the 4th quarter. BB&T Corp now owns 5,555 shares of the medical instruments supplier’s stock worth $1,189,000 after acquiring an additional 419 shares in the last quarter. 75.56% of the stock is owned by institutional investors and hedge funds.
BDX has been the topic of several recent research reports. Zacks Investment Research downgraded Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Friday, January 12th. Morgan Stanley upped their price target on Becton Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a report on Friday, November 3rd. Royal Bank of Canada restated a “hold” rating and set a $210.00 price target on shares of Becton Dickinson and in a report on Wednesday, October 25th. Stifel Nicolaus restated a “buy” rating and set a $245.00 price target on shares of Becton Dickinson and in a report on Friday, November 3rd. Finally, KeyCorp assumed coverage on Becton Dickinson and in a report on Friday, January 5th. They issued an “overweight” rating and a $260.00 price objective on the stock. Four research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. Becton Dickinson and currently has a consensus rating of “Buy” and a consensus price target of $237.27.
In other news, Director Timothy M. Ring sold 269,661 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $217.82, for a total value of $58,737,559.02. Following the completion of the sale, the director now directly owns 295,753 shares of the company’s stock, valued at approximately $64,420,918.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.00% of the stock is owned by company insiders.
Shares of Becton Dickinson and Co (NYSE:BDX) opened at $218.00 on Tuesday. The company has a quick ratio of 0.93, a current ratio of 1.54 and a debt-to-equity ratio of 1.04. The company has a market capitalization of $57,811.89, a P/E ratio of 166.41, a PEG ratio of 1.49 and a beta of 1.12. Becton Dickinson and Co has a 1-year low of $175.66 and a 1-year high of $248.39.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 EPS for the quarter, beating the consensus estimate of $2.41 by $0.07. The business had revenue of $3.08 billion during the quarter, compared to analysts’ expectations of $3.05 billion. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period last year, the firm earned $2.33 EPS. sell-side analysts anticipate that Becton Dickinson and Co will post 10.95 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 30th. Stockholders of record on Friday, March 9th will be issued a $0.75 dividend. The ex-dividend date of this dividend is Thursday, March 8th. This represents a $3.00 annualized dividend and a dividend yield of 1.38%. Becton Dickinson and’s dividend payout ratio is currently 229.01%.
COPYRIGHT VIOLATION NOTICE: This story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/13/becton-dickinson-and-co-bdx-shares-sold-by-jensen-investment-management-inc.html.
About Becton Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.